Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on January 28th, 2023%
Data in the chart are compiled by PatentSight, a service of LexisNexis, that show the seven leading holders of machine learning and other A.I. patents by company in 2017 and 2021. . . . → Read More: Infographic – Chinese Companies Lead in A.I. Patents
By Alan, on August 31st, 2022%
A joint venture with business development and bio-manufacturing companies aims to build new cell and gene therapy businesses to advance treatments from Mayo Clinic labs. . . . → Read More: Venture to Build Cell, Gene Therapy Businesses
By Alan, on July 8th, 2022%
Researchers analyzed medical and scientific databases with algorithms to identify eight previously unreported biomarkers contributing to neurodegeneration similar to ALS. . . . → Read More: AI Analytics Find New ALS Genetic Drug Targets
By Alan, on February 25th, 2022%
A clinical trial is set to begin testing the safety and chemical activity of a drug candidate for lung fibrosis, discovered and refined with artificial intelligence. . . . → Read More: Clinical Trial Set for AI-Driven Lung Fibrosis Drug
By Alan, on January 19th, 2022%
Clinical trial results show an immunotherapy licensed as a lower-priced cancer drug increases survival time in combination with chemotherapy. . . . → Read More: Trial Shows Immunotherapy Improves Lung Cancer Survival
By Alan, on February 25th, 2021%
A provider of drug discovery services based on artificial intelligence says in 18 months it identified and tested in mice a new drug for a chronic lung disease. . . . → Read More: AI Process Discovers, Tests Fibrosis Drug in 18 Months
By Alan, on December 18th, 2020%
A clinical trial conducted by National Institutes of Health is evaluating two more synthetic antibodies as treatments for patients hospitalized with Covid-19 infections. . . . → Read More: Large Trial Testing Covid-19 Antibody Therapies
By Alan, on December 15th, 2020%
Drug maker AbbVie is licensing a synthetic antibody to treat Covid-19 and SARS coronaviruses that the company began funding in June. . . . → Read More: AbbVie Acquires Coronavirus Antibody Therapy
By Alan, on October 3rd, 2020%
The report also highlights where the investments were made, with the geographic hubs or clusters attracting the most investments, this weekend’s infographic. . . . → Read More: Infographic – Global Climate Technology Hubs
By Alan, on August 19th, 2020%
Two biotechnology companies are developing a Covid-19 treatment that combines engineered antibodies and natural killer immune system cells. . . . → Read More: Biotechs, Univ. Labs Partner on Covid-19 Combo Therapy
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|